| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medication Errors | 179 | 2023 | 798 | 25.300 |
Why?
|
| Medical Order Entry Systems | 107 | 2021 | 545 | 22.730 |
Why?
|
| Decision Support Systems, Clinical | 127 | 2023 | 1164 | 18.190 |
Why?
|
| Electronic Health Records | 176 | 2024 | 4468 | 16.900 |
Why?
|
| Medical Records Systems, Computerized | 125 | 2021 | 1205 | 12.230 |
Why?
|
| Drug Therapy, Computer-Assisted | 52 | 2020 | 204 | 10.010 |
Why?
|
| Medical Informatics | 50 | 2022 | 745 | 7.730 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 46 | 2022 | 469 | 7.420 |
Why?
|
| Medical Errors | 72 | 2023 | 1297 | 6.680 |
Why?
|
| Safety Management | 61 | 2023 | 783 | 6.560 |
Why?
|
| Drug Interactions | 40 | 2020 | 1460 | 5.880 |
Why?
|
| Medication Systems, Hospital | 46 | 2020 | 158 | 5.470 |
Why?
|
| Diffusion of Innovation | 40 | 2020 | 725 | 5.190 |
Why?
|
| Hospital Information Systems | 38 | 2021 | 395 | 4.970 |
Why?
|
| Attitude to Computers | 38 | 2018 | 202 | 4.770 |
Why?
|
| Primary Health Care | 73 | 2024 | 4557 | 4.020 |
Why?
|
| Ambulatory Care | 52 | 2022 | 2708 | 3.930 |
Why?
|
| Electronic Prescribing | 24 | 2022 | 121 | 3.840 |
Why?
|
| Health Records, Personal | 13 | 2014 | 124 | 3.740 |
Why?
|
| Attitude of Health Personnel | 63 | 2023 | 3841 | 3.670 |
Why?
|
| Hospitals, Community | 14 | 2015 | 347 | 3.580 |
Why?
|
| Delivery of Health Care | 46 | 2024 | 5321 | 3.480 |
Why?
|
| Quality of Health Care | 64 | 2023 | 4369 | 3.440 |
Why?
|
| Patient-Centered Care | 26 | 2023 | 1438 | 3.280 |
Why?
|
| Physicians | 48 | 2022 | 4567 | 3.160 |
Why?
|
| User-Computer Interface | 44 | 2020 | 1431 | 3.090 |
Why?
|
| Infusion Pumps | 10 | 2023 | 163 | 3.040 |
Why?
|
| Internet | 31 | 2020 | 3056 | 3.010 |
Why?
|
| Humans | 937 | 2024 | 744366 | 2.910 |
Why?
|
| Documentation | 28 | 2022 | 871 | 2.770 |
Why?
|
| Risk Management | 31 | 2017 | 571 | 2.700 |
Why?
|
| Hospitals | 40 | 2023 | 3954 | 2.660 |
Why?
|
| Inpatients | 31 | 2023 | 2518 | 2.600 |
Why?
|
| Quality Assurance, Health Care | 40 | 2017 | 2212 | 2.580 |
Why?
|
| Patient Participation | 24 | 2020 | 1457 | 2.560 |
Why?
|
| Hospitals, Teaching | 28 | 2023 | 1180 | 2.500 |
Why?
|
| Hospitalization | 47 | 2023 | 10259 | 2.500 |
Why?
|
| Medical Record Linkage | 14 | 2014 | 284 | 2.450 |
Why?
|
| Quality Indicators, Health Care | 22 | 2024 | 1831 | 2.340 |
Why?
|
| Infusions, Intravenous | 14 | 2023 | 2274 | 2.290 |
Why?
|
| Drug Hypersensitivity | 19 | 2022 | 884 | 2.280 |
Why?
|
| Drug Prescriptions | 42 | 2021 | 1637 | 2.250 |
Why?
|
| Information Systems | 17 | 2018 | 410 | 2.250 |
Why?
|
| Artificial Intelligence | 16 | 2024 | 2213 | 2.250 |
Why?
|
| Electronic Mail | 13 | 2023 | 213 | 2.250 |
Why?
|
| Intensive Care Units | 31 | 2021 | 3680 | 2.240 |
Why?
|
| Clinical Pharmacy Information Systems | 18 | 2015 | 103 | 2.200 |
Why?
|
| Physicians, Primary Care | 10 | 2023 | 592 | 2.200 |
Why?
|
| Quality Improvement | 29 | 2024 | 3749 | 2.200 |
Why?
|
| Communication | 39 | 2023 | 3750 | 2.180 |
Why?
|
| Telemedicine | 24 | 2022 | 2872 | 2.150 |
Why?
|
| Safety | 17 | 2018 | 1186 | 2.070 |
Why?
|
| Iatrogenic Disease | 22 | 2013 | 547 | 2.040 |
Why?
|
| United States | 203 | 2023 | 69872 | 2.040 |
Why?
|
| Health Care Costs | 25 | 2023 | 3208 | 2.040 |
Why?
|
| Ambulatory Care Information Systems | 17 | 2015 | 86 | 2.040 |
Why?
|
| Accidental Falls | 16 | 2023 | 1062 | 2.020 |
Why?
|
| Pharmacy Service, Hospital | 17 | 2021 | 133 | 2.000 |
Why?
|
| Patient Satisfaction | 27 | 2020 | 3395 | 2.000 |
Why?
|
| Drug Monitoring | 20 | 2013 | 956 | 1.980 |
Why?
|
| Pharmaceutical Preparations | 25 | 2023 | 1070 | 1.940 |
Why?
|
| Academic Medical Centers | 42 | 2022 | 2760 | 1.910 |
Why?
|
| Continuity of Patient Care | 12 | 2018 | 1049 | 1.900 |
Why?
|
| Reminder Systems | 23 | 2018 | 371 | 1.870 |
Why?
|
| Ambulatory Care Facilities | 14 | 2023 | 934 | 1.780 |
Why?
|
| Medical Informatics Applications | 12 | 2020 | 186 | 1.730 |
Why?
|
| Outpatients | 15 | 2023 | 1487 | 1.720 |
Why?
|
| Practice Management, Medical | 7 | 2013 | 196 | 1.690 |
Why?
|
| Pharmacists | 14 | 2018 | 248 | 1.680 |
Why?
|
| Massachusetts | 72 | 2022 | 8662 | 1.650 |
Why?
|
| Organizational Innovation | 19 | 2019 | 559 | 1.630 |
Why?
|
| Internal Medicine | 13 | 2020 | 1009 | 1.610 |
Why?
|
| Data Collection | 45 | 2021 | 3339 | 1.610 |
Why?
|
| Workflow | 14 | 2020 | 847 | 1.580 |
Why?
|
| Medical Staff, Hospital | 14 | 2019 | 601 | 1.560 |
Why?
|
| Medical Audit | 22 | 2017 | 467 | 1.520 |
Why?
|
| Medical Records, Problem-Oriented | 6 | 2015 | 35 | 1.520 |
Why?
|
| Caregivers | 13 | 2021 | 2095 | 1.510 |
Why?
|
| Female | 348 | 2024 | 380193 | 1.490 |
Why?
|
| Information Dissemination | 9 | 2020 | 1099 | 1.480 |
Why?
|
| Health Services Research | 24 | 2017 | 1836 | 1.480 |
Why?
|
| Boston | 72 | 2021 | 9312 | 1.480 |
Why?
|
| Male | 329 | 2024 | 350115 | 1.470 |
Why?
|
| Health Plan Implementation | 12 | 2022 | 352 | 1.470 |
Why?
|
| Guideline Adherence | 20 | 2019 | 2265 | 1.450 |
Why?
|
| Patient Care | 9 | 2023 | 640 | 1.450 |
Why?
|
| Patient Care Management | 8 | 2021 | 306 | 1.430 |
Why?
|
| Patient Care Team | 20 | 2022 | 2531 | 1.410 |
Why?
|
| Middle Aged | 255 | 2023 | 213390 | 1.410 |
Why?
|
| Patient Discharge | 20 | 2022 | 3318 | 1.380 |
Why?
|
| Health Care Surveys | 35 | 2021 | 2453 | 1.370 |
Why?
|
| Clinical Laboratory Information Systems | 9 | 2017 | 108 | 1.360 |
Why?
|
| Patient Access to Records | 8 | 2020 | 118 | 1.350 |
Why?
|
| Decision Making, Computer-Assisted | 10 | 2010 | 150 | 1.340 |
Why?
|
| Diagnostic Errors | 11 | 2022 | 1257 | 1.330 |
Why?
|
| Medication Systems | 7 | 2015 | 31 | 1.310 |
Why?
|
| Diagnostic Tests, Routine | 8 | 2013 | 783 | 1.280 |
Why?
|
| Adult | 224 | 2024 | 214052 | 1.260 |
Why?
|
| Algorithms | 31 | 2024 | 13882 | 1.260 |
Why?
|
| Aged | 198 | 2023 | 163288 | 1.240 |
Why?
|
| Medicine | 14 | 2022 | 946 | 1.240 |
Why?
|
| Medication Reconciliation | 6 | 2023 | 151 | 1.220 |
Why?
|
| Professional Role | 9 | 2018 | 306 | 1.190 |
Why?
|
| Renal Insufficiency | 5 | 2021 | 804 | 1.180 |
Why?
|
| Physician-Patient Relations | 19 | 2022 | 3229 | 1.160 |
Why?
|
| Decision Support Techniques | 16 | 2017 | 1956 | 1.150 |
Why?
|
| Computers | 8 | 2016 | 612 | 1.150 |
Why?
|
| Physicians, Family | 10 | 2009 | 345 | 1.140 |
Why?
|
| Hyponatremia | 3 | 2016 | 298 | 1.120 |
Why?
|
| Hospital Administration | 7 | 2021 | 353 | 1.110 |
Why?
|
| Internationality | 10 | 2021 | 1002 | 1.110 |
Why?
|
| Professional-Patient Relations | 7 | 2018 | 737 | 1.110 |
Why?
|
| Medical Records | 20 | 2019 | 1413 | 1.100 |
Why?
|
| Computers, Handheld | 5 | 2016 | 208 | 1.090 |
Why?
|
| Patients | 9 | 2024 | 900 | 1.090 |
Why?
|
| Sepsis | 13 | 2022 | 2593 | 1.080 |
Why?
|
| Workload | 11 | 2020 | 849 | 1.080 |
Why?
|
| Cross-Sectional Studies | 50 | 2023 | 25039 | 1.080 |
Why?
|
| Clinical Alarms | 3 | 2016 | 52 | 1.070 |
Why?
|
| Government Regulation | 4 | 2018 | 522 | 1.060 |
Why?
|
| Health Priorities | 2 | 2019 | 380 | 1.050 |
Why?
|
| Hospitals, Psychiatric | 8 | 2018 | 332 | 1.050 |
Why?
|
| Commerce | 7 | 2021 | 592 | 1.040 |
Why?
|
| Medication Therapy Management | 3 | 2022 | 127 | 1.020 |
Why?
|
| Organizational Culture | 12 | 2017 | 510 | 1.010 |
Why?
|
| Health Services Misuse | 4 | 2017 | 243 | 1.010 |
Why?
|
| Telephone | 4 | 2022 | 617 | 1.000 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2023 | 1458 | 1.000 |
Why?
|
| Delivery of Health Care, Integrated | 13 | 2020 | 941 | 1.000 |
Why?
|
| Health Personnel | 11 | 2020 | 3219 | 0.990 |
Why?
|
| Prescription Drugs | 6 | 2012 | 595 | 0.990 |
Why?
|
| Time and Motion Studies | 8 | 2018 | 149 | 0.990 |
Why?
|
| Cross Infection | 9 | 2015 | 1417 | 0.990 |
Why?
|
| Nursing Homes | 6 | 2022 | 1036 | 0.980 |
Why?
|
| Bacteremia | 9 | 2015 | 963 | 0.980 |
Why?
|
| Job Satisfaction | 8 | 2023 | 534 | 0.980 |
Why?
|
| Health Policy | 15 | 2022 | 2661 | 0.980 |
Why?
|
| Computer Security | 7 | 2018 | 262 | 0.970 |
Why?
|
| Patient Care Planning | 7 | 2017 | 921 | 0.970 |
Why?
|
| Malpractice | 8 | 2022 | 572 | 0.960 |
Why?
|
| Analgesia, Patient-Controlled | 2 | 2014 | 109 | 0.940 |
Why?
|
| Cooperative Behavior | 9 | 2019 | 1504 | 0.920 |
Why?
|
| Chronic Disease | 13 | 2017 | 9145 | 0.910 |
Why?
|
| Pharmaceutical Services | 6 | 2021 | 140 | 0.910 |
Why?
|
| Hospital Communication Systems | 3 | 2016 | 51 | 0.910 |
Why?
|
| Monitoring, Physiologic | 11 | 2023 | 1739 | 0.900 |
Why?
|
| Anaphylaxis | 4 | 2018 | 746 | 0.890 |
Why?
|
| Burnout, Professional | 6 | 2023 | 694 | 0.890 |
Why?
|
| Hypertension | 15 | 2022 | 8479 | 0.880 |
Why?
|
| Hypernatremia | 2 | 2013 | 82 | 0.880 |
Why?
|
| Hypotension | 2 | 2021 | 884 | 0.870 |
Why?
|
| Systems Integration | 15 | 2020 | 440 | 0.870 |
Why?
|
| Medical History Taking | 7 | 2017 | 784 | 0.870 |
Why?
|
| Health Services | 5 | 2012 | 758 | 0.870 |
Why?
|
| Ficusin | 1 | 2022 | 15 | 0.860 |
Why?
|
| Referral and Consultation | 15 | 2018 | 3531 | 0.860 |
Why?
|
| Hospital Costs | 11 | 2014 | 985 | 0.860 |
Why?
|
| Critical Care | 12 | 2023 | 2647 | 0.850 |
Why?
|
| Antifungal Agents | 5 | 2006 | 729 | 0.840 |
Why?
|
| Prospective Studies | 91 | 2023 | 53290 | 0.840 |
Why?
|
| DNA, Superhelical | 1 | 2022 | 50 | 0.840 |
Why?
|
| Databases as Topic | 2 | 2022 | 475 | 0.830 |
Why?
|
| Retrospective Studies | 91 | 2024 | 77460 | 0.830 |
Why?
|
| Knowledge Bases | 6 | 2020 | 85 | 0.820 |
Why?
|
| Organizational Case Studies | 12 | 2021 | 299 | 0.810 |
Why?
|
| Pandemics | 16 | 2024 | 8385 | 0.810 |
Why?
|
| Office Visits | 6 | 2022 | 598 | 0.800 |
Why?
|
| Anti-Infective Agents | 4 | 2019 | 974 | 0.800 |
Why?
|
| Subacute Care | 2 | 2021 | 168 | 0.800 |
Why?
|
| Health Care Reform | 8 | 2017 | 1261 | 0.790 |
Why?
|
| Hospitals, Urban | 10 | 2011 | 499 | 0.790 |
Why?
|
| Interviews as Topic | 18 | 2021 | 2539 | 0.780 |
Why?
|
| Cost Savings | 13 | 2023 | 925 | 0.780 |
Why?
|
| Homes for the Aged | 2 | 2022 | 260 | 0.770 |
Why?
|
| Specialization | 10 | 2012 | 776 | 0.770 |
Why?
|
| Drug Therapy | 8 | 2008 | 497 | 0.760 |
Why?
|
| Information Management | 5 | 2016 | 101 | 0.740 |
Why?
|
| Diabetes Mellitus | 15 | 2022 | 5749 | 0.740 |
Why?
|
| Clinical Laboratory Techniques | 12 | 2009 | 738 | 0.740 |
Why?
|
| Gender Identity | 4 | 2024 | 687 | 0.740 |
Why?
|
| Confidentiality | 9 | 2018 | 612 | 0.730 |
Why?
|
| Models, Theoretical | 8 | 2019 | 3589 | 0.730 |
Why?
|
| Access to Information | 4 | 2016 | 320 | 0.720 |
Why?
|
| Aged, 80 and over | 76 | 2021 | 57776 | 0.720 |
Why?
|
| Escherichia coli | 6 | 2023 | 4217 | 0.720 |
Why?
|
| Health Care Sector | 3 | 2016 | 194 | 0.710 |
Why?
|
| Pressure Ulcer | 3 | 2021 | 155 | 0.700 |
Why?
|
| Professional Practice | 4 | 2019 | 326 | 0.700 |
Why?
|
| Nursing Staff, Hospital | 9 | 2021 | 346 | 0.690 |
Why?
|
| Overweight | 5 | 2023 | 2371 | 0.690 |
Why?
|
| Scleroderma, Systemic | 1 | 2023 | 323 | 0.680 |
Why?
|
| Bibliometrics | 2 | 2017 | 339 | 0.680 |
Why?
|
| Renal Insufficiency, Chronic | 9 | 2021 | 2200 | 0.680 |
Why?
|
| Drug Information Services | 2 | 2010 | 51 | 0.680 |
Why?
|
| Computer Literacy | 6 | 2022 | 43 | 0.680 |
Why?
|
| Medication Adherence | 6 | 2022 | 2063 | 0.680 |
Why?
|
| Total Quality Management | 8 | 2008 | 274 | 0.670 |
Why?
|
| Software | 22 | 2022 | 4441 | 0.660 |
Why?
|
| Practice Guidelines as Topic | 22 | 2020 | 7282 | 0.660 |
Why?
|
| Somatoform Disorders | 4 | 2008 | 423 | 0.660 |
Why?
|
| Biomedical Technology | 5 | 2019 | 220 | 0.660 |
Why?
|
| Evidence-Based Medicine | 14 | 2020 | 3611 | 0.660 |
Why?
|
| Hospitals, University | 11 | 2016 | 570 | 0.650 |
Why?
|
| Length of Stay | 25 | 2021 | 6311 | 0.650 |
Why?
|
| Pharmacogenetics | 2 | 2021 | 674 | 0.650 |
Why?
|
| Drug Labeling | 3 | 2010 | 233 | 0.620 |
Why?
|
| Qualitative Research | 16 | 2023 | 2682 | 0.620 |
Why?
|
| American Recovery and Reinvestment Act | 4 | 2022 | 71 | 0.610 |
Why?
|
| Computer Systems | 7 | 2011 | 483 | 0.610 |
Why?
|
| DNA Replication | 3 | 2023 | 1399 | 0.600 |
Why?
|
| Republic of Korea | 6 | 2019 | 538 | 0.600 |
Why?
|
| United States Food and Drug Administration | 7 | 2018 | 1584 | 0.600 |
Why?
|
| Interferon-beta | 3 | 2009 | 324 | 0.600 |
Why?
|
| Patient Transfer | 4 | 2023 | 762 | 0.600 |
Why?
|
| Cost-Benefit Analysis | 23 | 2023 | 5388 | 0.600 |
Why?
|
| Economics, Hospital | 2 | 2009 | 213 | 0.590 |
Why?
|
| Information Storage and Retrieval | 12 | 2008 | 824 | 0.590 |
Why?
|
| Quality Control | 6 | 2016 | 841 | 0.590 |
Why?
|
| Group Practice | 2 | 2012 | 149 | 0.590 |
Why?
|
| Hospital Administrators | 2 | 2018 | 57 | 0.580 |
Why?
|
| Data Mining | 4 | 2024 | 537 | 0.580 |
Why?
|
| Regression Analysis | 19 | 2021 | 6459 | 0.570 |
Why?
|
| Cohort Studies | 62 | 2021 | 40559 | 0.570 |
Why?
|
| Perception | 6 | 2021 | 1198 | 0.570 |
Why?
|
| Wounds and Injuries | 5 | 2020 | 2400 | 0.570 |
Why?
|
| Acute Kidney Injury | 5 | 2021 | 1968 | 0.560 |
Why?
|
| Databases, Factual | 18 | 2023 | 7730 | 0.560 |
Why?
|
| Hospitals, Private | 1 | 2016 | 63 | 0.550 |
Why?
|
| Program Evaluation | 7 | 2021 | 2488 | 0.550 |
Why?
|
| Health Resources | 7 | 2017 | 911 | 0.540 |
Why?
|
| Nursing Informatics | 3 | 2020 | 42 | 0.530 |
Why?
|
| Systemic Inflammatory Response Syndrome | 6 | 2014 | 612 | 0.530 |
Why?
|
| Antihypertensive Agents | 9 | 2021 | 2047 | 0.520 |
Why?
|
| Healthcare Disparities | 8 | 2023 | 3154 | 0.520 |
Why?
|
| Personnel, Hospital | 6 | 2021 | 283 | 0.520 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2019 | 1516 | 0.520 |
Why?
|
| Internship and Residency | 14 | 2021 | 5791 | 0.510 |
Why?
|
| Intention | 2 | 2016 | 342 | 0.510 |
Why?
|
| Self Care | 8 | 2016 | 786 | 0.510 |
Why?
|
| Language | 5 | 2022 | 1471 | 0.510 |
Why?
|
| Young Adult | 35 | 2023 | 56429 | 0.510 |
Why?
|
| Azoles | 2 | 2005 | 20 | 0.510 |
Why?
|
| Hospitals, Public | 1 | 2016 | 207 | 0.500 |
Why?
|
| Teaching Rounds | 1 | 2019 | 253 | 0.500 |
Why?
|
| Logistic Models | 29 | 2022 | 13409 | 0.500 |
Why?
|
| Analgesics, Opioid | 7 | 2022 | 3677 | 0.500 |
Why?
|
| Needs Assessment | 2 | 2020 | 1147 | 0.500 |
Why?
|
| Patient Acceptance of Health Care | 6 | 2021 | 3020 | 0.490 |
Why?
|
| Equipment Failure Analysis | 2 | 2018 | 868 | 0.490 |
Why?
|
| Postoperative Complications | 10 | 2021 | 15297 | 0.490 |
Why?
|
| Unnecessary Procedures | 5 | 2007 | 432 | 0.490 |
Why?
|
| Medicare | 16 | 2023 | 6566 | 0.490 |
Why?
|
| Benchmarking | 5 | 2009 | 1042 | 0.490 |
Why?
|
| Policy Making | 7 | 2014 | 554 | 0.490 |
Why?
|
| Office Management | 2 | 2004 | 14 | 0.480 |
Why?
|
| Disease Management | 5 | 2014 | 2460 | 0.480 |
Why?
|
| Risk Assessment | 24 | 2021 | 23336 | 0.480 |
Why?
|
| Patient Education as Topic | 10 | 2018 | 2278 | 0.480 |
Why?
|
| Outpatient Clinics, Hospital | 8 | 2017 | 392 | 0.480 |
Why?
|
| Efficiency, Organizational | 11 | 2017 | 695 | 0.480 |
Why?
|
| Obesity | 8 | 2023 | 12746 | 0.470 |
Why?
|
| Pilot Projects | 20 | 2019 | 8319 | 0.470 |
Why?
|
| Fatigue Syndrome, Chronic | 5 | 1996 | 214 | 0.470 |
Why?
|
| Canada | 13 | 2021 | 2065 | 0.470 |
Why?
|
| Adjuvants, Immunologic | 3 | 2009 | 1000 | 0.470 |
Why?
|
| Intelligence | 1 | 2019 | 920 | 0.470 |
Why?
|
| Patient Readmission | 8 | 2022 | 3116 | 0.460 |
Why?
|
| Resource Allocation | 1 | 2016 | 341 | 0.460 |
Why?
|
| Multivariate Analysis | 28 | 2012 | 12244 | 0.460 |
Why?
|
| Health Literacy | 2 | 2020 | 414 | 0.460 |
Why?
|
| Interprofessional Relations | 5 | 2018 | 1011 | 0.460 |
Why?
|
| Consumer Health Information | 1 | 2016 | 211 | 0.450 |
Why?
|
| Capitation Fee | 5 | 2000 | 116 | 0.450 |
Why?
|
| Bioterrorism | 2 | 2004 | 143 | 0.450 |
Why?
|
| Comorbidity | 18 | 2020 | 10388 | 0.450 |
Why?
|
| Long-Term Care | 6 | 2008 | 607 | 0.450 |
Why?
|
| Drug Utilization Review | 3 | 2007 | 245 | 0.440 |
Why?
|
| Risk Factors | 67 | 2021 | 72296 | 0.440 |
Why?
|
| Asthma | 7 | 2022 | 6010 | 0.440 |
Why?
|
| Fee-for-Service Plans | 2 | 2017 | 694 | 0.440 |
Why?
|
| Vaccines | 1 | 2021 | 823 | 0.430 |
Why?
|
| Catheters, Indwelling | 1 | 2015 | 426 | 0.430 |
Why?
|
| Costs and Cost Analysis | 14 | 2016 | 1680 | 0.430 |
Why?
|
| Research Personnel | 1 | 2017 | 573 | 0.430 |
Why?
|
| Forecasting | 11 | 2022 | 2951 | 0.430 |
Why?
|
| Community Networks | 3 | 2008 | 203 | 0.430 |
Why?
|
| Periodicals as Topic | 3 | 2017 | 1431 | 0.420 |
Why?
|
| Incidence | 31 | 2023 | 20952 | 0.420 |
Why?
|
| Epinephrine | 1 | 2016 | 792 | 0.420 |
Why?
|
| Reproducibility of Results | 25 | 2024 | 19905 | 0.420 |
Why?
|
| Hospital Units | 5 | 2013 | 141 | 0.420 |
Why?
|
| Hypertension, Pulmonary | 1 | 2023 | 1534 | 0.420 |
Why?
|
| Urination Disorders | 1 | 2013 | 241 | 0.420 |
Why?
|
| Speech Recognition Software | 3 | 2019 | 72 | 0.410 |
Why?
|
| Clinical Competence | 11 | 2018 | 4687 | 0.410 |
Why?
|
| Nursing Staff | 2 | 2012 | 129 | 0.410 |
Why?
|
| Models, Statistical | 6 | 2017 | 5101 | 0.410 |
Why?
|
| Diabetes Mellitus, Type 2 | 12 | 2023 | 11726 | 0.410 |
Why?
|
| Electronics | 6 | 2022 | 322 | 0.410 |
Why?
|
| Polypharmacy | 2 | 2007 | 294 | 0.410 |
Why?
|
| Inservice Training | 3 | 2017 | 392 | 0.410 |
Why?
|
| Hospital Charges | 7 | 2012 | 362 | 0.410 |
Why?
|
| Mass Screening | 7 | 2022 | 5253 | 0.410 |
Why?
|
| Psychotropic Drugs | 3 | 2008 | 894 | 0.400 |
Why?
|
| Product Labeling | 1 | 2012 | 79 | 0.400 |
Why?
|
| Blood Specimen Collection | 4 | 2017 | 246 | 0.400 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2011 | 76 | 0.400 |
Why?
|
| Health Facility Merger | 1 | 2012 | 53 | 0.400 |
Why?
|
| Information Services | 4 | 2010 | 244 | 0.400 |
Why?
|
| Database Management Systems | 5 | 2007 | 270 | 0.400 |
Why?
|
| Feedback | 3 | 2021 | 795 | 0.400 |
Why?
|
| Personnel Staffing and Scheduling | 7 | 2019 | 500 | 0.400 |
Why?
|
| Leadership | 8 | 2023 | 1357 | 0.390 |
Why?
|
| Cost of Illness | 5 | 2019 | 1860 | 0.390 |
Why?
|
| Socioeconomic Factors | 14 | 2022 | 7785 | 0.390 |
Why?
|
| Health Behavior | 3 | 2020 | 2635 | 0.390 |
Why?
|
| Perioperative Care | 2 | 2016 | 1002 | 0.390 |
Why?
|
| International Cooperation | 4 | 2020 | 1420 | 0.390 |
Why?
|
| Amphotericin B | 2 | 2001 | 137 | 0.390 |
Why?
|
| Adolescent | 49 | 2024 | 85779 | 0.380 |
Why?
|
| Conflict of Interest | 2 | 2014 | 544 | 0.380 |
Why?
|
| International Classification of Diseases | 4 | 2023 | 867 | 0.380 |
Why?
|
| Informatics | 2 | 2018 | 72 | 0.380 |
Why?
|
| Vital Signs | 2 | 2021 | 142 | 0.380 |
Why?
|
| Odds Ratio | 18 | 2020 | 9849 | 0.380 |
Why?
|
| Consumer Product Safety | 2 | 2010 | 122 | 0.380 |
Why?
|
| Evaluation Studies as Topic | 8 | 2016 | 1681 | 0.380 |
Why?
|
| Work Schedule Tolerance | 5 | 2021 | 563 | 0.380 |
Why?
|
| Vulnerable Populations | 1 | 2016 | 686 | 0.380 |
Why?
|
| Problem Solving | 2 | 2019 | 440 | 0.380 |
Why?
|
| Management Information Systems | 2 | 2008 | 50 | 0.370 |
Why?
|
| Certification | 3 | 2014 | 423 | 0.370 |
Why?
|
| Stereotyping | 2 | 2023 | 241 | 0.370 |
Why?
|
| Clinical Coding | 2 | 2015 | 171 | 0.370 |
Why?
|
| Quinoxalines | 1 | 2012 | 290 | 0.370 |
Why?
|
| Culture | 1 | 2014 | 633 | 0.370 |
Why?
|
| Nicotinic Agonists | 1 | 2012 | 271 | 0.360 |
Why?
|
| Psychometrics | 7 | 2022 | 3003 | 0.360 |
Why?
|
| Technology, Pharmaceutical | 2 | 2007 | 84 | 0.360 |
Why?
|
| Health Planning | 2 | 2011 | 238 | 0.360 |
Why?
|
| Hospital Mortality | 12 | 2021 | 5316 | 0.360 |
Why?
|
| Computer Communication Networks | 3 | 2004 | 295 | 0.360 |
Why?
|
| Health Facilities | 3 | 2024 | 572 | 0.360 |
Why?
|
| Benzazepines | 1 | 2012 | 326 | 0.360 |
Why?
|
| Blood | 5 | 2015 | 598 | 0.360 |
Why?
|
| Sex Factors | 14 | 2020 | 10400 | 0.360 |
Why?
|
| Kidney Diseases | 2 | 2013 | 2148 | 0.360 |
Why?
|
| Severity of Illness Index | 14 | 2020 | 15535 | 0.350 |
Why?
|
| Emergency Service, Hospital | 10 | 2022 | 7658 | 0.350 |
Why?
|
| Genetic Testing | 2 | 2013 | 3444 | 0.350 |
Why?
|
| Reference Books, Medical | 3 | 2006 | 22 | 0.350 |
Why?
|
| Natural Language Processing | 8 | 2022 | 1041 | 0.350 |
Why?
|
| Cost Control | 3 | 2012 | 624 | 0.350 |
Why?
|
| Cardiology | 2 | 2019 | 1668 | 0.350 |
Why?
|
| Disclosure | 3 | 2014 | 736 | 0.350 |
Why?
|
| Fluconazole | 2 | 2006 | 146 | 0.350 |
Why?
|
| Rural Population | 3 | 2020 | 2207 | 0.340 |
Why?
|
| Technology Assessment, Biomedical | 3 | 2009 | 306 | 0.340 |
Why?
|
| Therapeutic Human Experimentation | 1 | 2009 | 43 | 0.340 |
Why?
|
| Health Services Needs and Demand | 4 | 2016 | 1410 | 0.340 |
Why?
|
| Urban Population | 4 | 2015 | 2022 | 0.340 |
Why?
|
| Weight Loss | 1 | 2020 | 2625 | 0.340 |
Why?
|
| Infection Control | 2 | 2021 | 965 | 0.340 |
Why?
|
| Vancomycin | 4 | 2013 | 501 | 0.330 |
Why?
|
| Hypnotics and Sedatives | 3 | 2013 | 1162 | 0.330 |
Why?
|
| Time Factors | 27 | 2021 | 40075 | 0.330 |
Why?
|
| Amiodarone | 2 | 2016 | 212 | 0.330 |
Why?
|
| Chi-Square Distribution | 10 | 2020 | 3508 | 0.330 |
Why?
|
| Bayes Theorem | 3 | 2022 | 2307 | 0.330 |
Why?
|
| Therapeutics | 2 | 2007 | 116 | 0.330 |
Why?
|
| Diagnosis-Related Groups | 10 | 2014 | 455 | 0.320 |
Why?
|
| Inappropriate Prescribing | 1 | 2011 | 202 | 0.320 |
Why?
|
| Health Knowledge, Attitudes, Practice | 11 | 2019 | 3922 | 0.320 |
Why?
|
| Pediatrics | 6 | 2018 | 3475 | 0.320 |
Why?
|
| Time Management | 2 | 2005 | 50 | 0.320 |
Why?
|
| Prevalence | 15 | 2020 | 15221 | 0.320 |
Why?
|
| Coronary Care Units | 2 | 2008 | 214 | 0.320 |
Why?
|
| Family | 7 | 2022 | 3147 | 0.320 |
Why?
|
| Personal Satisfaction | 2 | 2023 | 643 | 0.310 |
Why?
|
| Community Health Services | 1 | 2013 | 650 | 0.310 |
Why?
|
| End Stage Liver Disease | 1 | 2012 | 314 | 0.310 |
Why?
|
| Anticoagulants | 10 | 2024 | 4600 | 0.310 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3135 | 0.310 |
Why?
|
| Social Values | 1 | 2009 | 224 | 0.310 |
Why?
|
| Arthroplasty, Replacement, Hip | 4 | 2022 | 1462 | 0.310 |
Why?
|
| Health Planning Councils | 1 | 2007 | 11 | 0.310 |
Why?
|
| Pharmacies | 4 | 2011 | 150 | 0.310 |
Why?
|
| Patient Admission | 6 | 2006 | 1380 | 0.310 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3242 | 0.310 |
Why?
|
| Decision Making | 8 | 2017 | 3888 | 0.310 |
Why?
|
| Liver Function Tests | 3 | 2012 | 528 | 0.310 |
Why?
|
| Pharmacoepidemiology | 4 | 2018 | 323 | 0.310 |
Why?
|
| England | 9 | 2019 | 522 | 0.310 |
Why?
|
| Technology | 4 | 2021 | 304 | 0.310 |
Why?
|
| Education, Medical | 5 | 2024 | 1722 | 0.310 |
Why?
|
| Pharyngitis | 2 | 2006 | 215 | 0.310 |
Why?
|
| Software Design | 5 | 2016 | 176 | 0.300 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 12356 | 0.300 |
Why?
|
| Observation | 4 | 2016 | 312 | 0.300 |
Why?
|
| Data Display | 2 | 2018 | 182 | 0.300 |
Why?
|
| Emergencies | 2 | 2004 | 1170 | 0.300 |
Why?
|
| Multiple Sclerosis | 5 | 2013 | 3079 | 0.300 |
Why?
|
| Food Hypersensitivity | 3 | 2022 | 622 | 0.300 |
Why?
|
| Coronary Artery Bypass | 8 | 2002 | 2288 | 0.290 |
Why?
|
| Valproic Acid | 3 | 2006 | 445 | 0.290 |
Why?
|
| Terminology as Topic | 5 | 2015 | 1547 | 0.290 |
Why?
|
| Public Opinion | 3 | 2022 | 477 | 0.290 |
Why?
|
| DNA, Bacterial | 3 | 2022 | 1465 | 0.290 |
Why?
|
| Diagnosis, Computer-Assisted | 5 | 2010 | 719 | 0.290 |
Why?
|
| Vocabulary, Controlled | 4 | 2018 | 170 | 0.290 |
Why?
|
| Students, Medical | 2 | 2019 | 1862 | 0.290 |
Why?
|
| Urinary Bladder | 1 | 2013 | 1173 | 0.290 |
Why?
|
| Nursing Records | 3 | 2020 | 28 | 0.290 |
Why?
|
| Fatigue | 3 | 2009 | 1531 | 0.290 |
Why?
|
| United States Indian Health Service | 1 | 2007 | 32 | 0.290 |
Why?
|
| Patient Rights | 1 | 2007 | 126 | 0.290 |
Why?
|
| Anticonvulsants | 4 | 2004 | 1916 | 0.290 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2009 | 320 | 0.290 |
Why?
|
| Antidepressive Agents | 4 | 2020 | 2838 | 0.280 |
Why?
|
| Anthrax | 2 | 2004 | 88 | 0.280 |
Why?
|
| Publishing | 2 | 2013 | 833 | 0.280 |
Why?
|
| Age Factors | 18 | 2020 | 18373 | 0.280 |
Why?
|
| Mycoses | 2 | 2006 | 376 | 0.280 |
Why?
|
| Nursing Audit | 1 | 2006 | 13 | 0.280 |
Why?
|
| Nursing Service, Hospital | 1 | 2006 | 17 | 0.280 |
Why?
|
| Family Health | 2 | 2013 | 1281 | 0.280 |
Why?
|
| Cough | 3 | 2022 | 555 | 0.280 |
Why?
|
| Drug and Narcotic Control | 1 | 2007 | 146 | 0.280 |
Why?
|
| Hypercholesterolemia | 3 | 2005 | 1151 | 0.280 |
Why?
|
| MEDLINE | 1 | 2006 | 125 | 0.280 |
Why?
|
| Research Design | 12 | 2023 | 5984 | 0.280 |
Why?
|
| Case-Control Studies | 21 | 2023 | 21748 | 0.270 |
Why?
|
| Japan | 7 | 2023 | 1360 | 0.270 |
Why?
|
| New England | 4 | 2019 | 1022 | 0.270 |
Why?
|
| State Medicine | 4 | 2016 | 217 | 0.270 |
Why?
|
| Tablets | 1 | 2006 | 145 | 0.270 |
Why?
|
| Neoplasms | 8 | 2022 | 21696 | 0.270 |
Why?
|
| Online Systems | 1 | 2006 | 184 | 0.260 |
Why?
|
| Health Services Accessibility | 2 | 2022 | 5135 | 0.260 |
Why?
|
| Stiff-Person Syndrome | 1 | 2005 | 28 | 0.260 |
Why?
|
| Warfarin | 3 | 2021 | 1497 | 0.260 |
Why?
|
| Mental Disorders | 5 | 2008 | 6598 | 0.260 |
Why?
|
| Medical Oncology | 4 | 2021 | 2267 | 0.260 |
Why?
|
| Focus Groups | 6 | 2022 | 1321 | 0.260 |
Why?
|
| Medical Informatics Computing | 1 | 2005 | 25 | 0.260 |
Why?
|
| Lithium Compounds | 1 | 2006 | 225 | 0.250 |
Why?
|
| Venous Thrombosis | 1 | 2014 | 1239 | 0.250 |
Why?
|
| Research | 6 | 2020 | 1999 | 0.250 |
Why?
|
| Critical Illness | 2 | 2010 | 2670 | 0.250 |
Why?
|
| Hypoglycemic Agents | 7 | 2021 | 2873 | 0.250 |
Why?
|
| Point-of-Care Systems | 7 | 2016 | 1178 | 0.250 |
Why?
|
| Depression | 4 | 2020 | 7759 | 0.250 |
Why?
|
| Directive Counseling | 1 | 2006 | 166 | 0.250 |
Why?
|
| Saudi Arabia | 2 | 2016 | 209 | 0.250 |
Why?
|
| Public Policy | 3 | 2018 | 572 | 0.240 |
Why?
|
| Teaching | 1 | 2012 | 1174 | 0.240 |
Why?
|
| Exercise | 1 | 2020 | 5615 | 0.240 |
Why?
|
| Managed Care Programs | 6 | 2000 | 950 | 0.240 |
Why?
|
| Forms and Records Control | 5 | 2015 | 160 | 0.240 |
Why?
|
| Endotoxins | 2 | 1998 | 527 | 0.240 |
Why?
|
| Software Validation | 3 | 2003 | 59 | 0.230 |
Why?
|
| Drug Costs | 5 | 2015 | 1105 | 0.230 |
Why?
|
| Nursing Care | 1 | 2004 | 74 | 0.230 |
Why?
|
| Societies, Scientific | 1 | 2005 | 220 | 0.230 |
Why?
|
| Platelet Transfusion | 1 | 2007 | 314 | 0.230 |
Why?
|
| Hospitals, State | 1 | 2003 | 29 | 0.230 |
Why?
|
| Nurses | 5 | 2018 | 2462 | 0.230 |
Why?
|
| Drug Utilization | 9 | 2015 | 1183 | 0.230 |
Why?
|
| Population Surveillance | 5 | 2016 | 2616 | 0.230 |
Why?
|
| Uridine Triphosphate | 1 | 2023 | 26 | 0.230 |
Why?
|
| Analysis of Variance | 9 | 2016 | 6366 | 0.230 |
Why?
|
| Models, Psychological | 1 | 2008 | 811 | 0.230 |
Why?
|
| Psychiatry | 2 | 2008 | 1695 | 0.230 |
Why?
|
| Random Allocation | 9 | 2018 | 2428 | 0.230 |
Why?
|
| Acute Coronary Syndrome | 2 | 2014 | 2337 | 0.220 |
Why?
|
| Mycophenolic Acid | 1 | 2005 | 343 | 0.220 |
Why?
|
| Gynecology | 2 | 2009 | 513 | 0.220 |
Why?
|
| Chromosomes, Bacterial | 2 | 2022 | 282 | 0.220 |
Why?
|
| Finland | 2 | 2017 | 602 | 0.220 |
Why?
|
| Psychiatric Department, Hospital | 1 | 2003 | 135 | 0.220 |
Why?
|
| Endocrine System Diseases | 1 | 2005 | 248 | 0.220 |
Why?
|
| Heart Failure | 4 | 2016 | 10895 | 0.220 |
Why?
|
| Antimanic Agents | 1 | 2006 | 522 | 0.220 |
Why?
|
| Emotions | 1 | 2014 | 2659 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 10 | 2019 | 7182 | 0.220 |
Why?
|
| Bronchial Spasm | 1 | 2022 | 73 | 0.220 |
Why?
|
| Checklist | 3 | 2017 | 833 | 0.220 |
Why?
|
| Acute Disease | 8 | 2018 | 7147 | 0.220 |
Why?
|
| Diagnostic Techniques and Procedures | 3 | 2012 | 214 | 0.220 |
Why?
|
| Meningioma | 2 | 2021 | 1209 | 0.210 |
Why?
|
| Surgery Department, Hospital | 2 | 2014 | 175 | 0.210 |
Why?
|
| Immunocompromised Host | 2 | 2009 | 847 | 0.210 |
Why?
|
| Emergency Medical Services | 2 | 2014 | 1917 | 0.210 |
Why?
|
| Hospital-Physician Joint Ventures | 2 | 1999 | 30 | 0.210 |
Why?
|
| Diuretics | 4 | 2019 | 591 | 0.210 |
Why?
|
| Meningeal Neoplasms | 2 | 2021 | 1241 | 0.210 |
Why?
|
| Predictive Value of Tests | 15 | 2013 | 15078 | 0.210 |
Why?
|
| Myocardial Infarction | 6 | 2014 | 11718 | 0.210 |
Why?
|
| Denmark | 3 | 2016 | 738 | 0.210 |
Why?
|
| Erythrocyte Transfusion | 1 | 2007 | 565 | 0.210 |
Why?
|
| Patient Compliance | 3 | 2001 | 2684 | 0.210 |
Why?
|
| Pain | 5 | 2023 | 4988 | 0.200 |
Why?
|
| Osteoporosis | 3 | 2011 | 1579 | 0.200 |
Why?
|
| Microcomputers | 1 | 2002 | 147 | 0.200 |
Why?
|
| Telecommunications | 1 | 2002 | 80 | 0.200 |
Why?
|
| Patient Identification Systems | 2 | 2014 | 79 | 0.200 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2024 | 160 | 0.200 |
Why?
|
| Obstetrics | 2 | 2009 | 658 | 0.200 |
Why?
|
| Physician Executives | 1 | 2002 | 128 | 0.200 |
Why?
|
| National Health Programs | 4 | 2013 | 445 | 0.200 |
Why?
|
| Efficiency | 2 | 2003 | 462 | 0.200 |
Why?
|
| Public Health | 3 | 2023 | 2602 | 0.200 |
Why?
|
| Otitis Media with Effusion | 1 | 2023 | 114 | 0.200 |
Why?
|
| Medicaid | 4 | 2013 | 2737 | 0.200 |
Why?
|
| Israel | 3 | 2016 | 796 | 0.200 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 2375 | 0.200 |
Why?
|
| Radio Frequency Identification Device | 1 | 2021 | 21 | 0.200 |
Why?
|
| Consensus | 8 | 2024 | 2960 | 0.200 |
Why?
|
| Creatinine | 6 | 2018 | 1919 | 0.200 |
Why?
|
| Taiwan | 4 | 2021 | 496 | 0.200 |
Why?
|
| Preoperative Period | 2 | 2014 | 550 | 0.200 |
Why?
|
| ROC Curve | 8 | 2021 | 3528 | 0.200 |
Why?
|
| United States Agency for Healthcare Research and Quality | 4 | 2018 | 92 | 0.200 |
Why?
|
| Education, Medical, Continuing | 1 | 2007 | 840 | 0.200 |
Why?
|
| Evidence-Based Nursing | 1 | 2020 | 16 | 0.190 |
Why?
|
| Hypochondriasis | 1 | 2001 | 92 | 0.190 |
Why?
|
| Patient Selection | 4 | 2019 | 4216 | 0.190 |
Why?
|
| Program Development | 4 | 2017 | 1316 | 0.190 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 4153 | 0.190 |
Why?
|
| Gastrointestinal Diseases | 2 | 2009 | 1170 | 0.190 |
Why?
|
| Residence Characteristics | 3 | 2019 | 2050 | 0.190 |
Why?
|
| Occupational Diseases | 1 | 2009 | 1469 | 0.190 |
Why?
|
| Thyroxine | 1 | 2004 | 667 | 0.190 |
Why?
|
| Reimbursement, Incentive | 3 | 2017 | 540 | 0.190 |
Why?
|
| Australia | 5 | 2007 | 1167 | 0.190 |
Why?
|
| Europe | 3 | 2022 | 3338 | 0.190 |
Why?
|
| Ownership | 2 | 2023 | 332 | 0.190 |
Why?
|
| Genetic Variation | 1 | 2016 | 6542 | 0.190 |
Why?
|
| Charcoal | 1 | 2000 | 62 | 0.190 |
Why?
|
| Pain, Postoperative | 2 | 2021 | 1643 | 0.190 |
Why?
|
| Attitude to Health | 5 | 2018 | 2052 | 0.190 |
Why?
|
| Literature | 1 | 2000 | 16 | 0.190 |
Why?
|
| Vitamin K 1 | 1 | 2000 | 48 | 0.190 |
Why?
|
| Otitis Media | 1 | 2023 | 277 | 0.190 |
Why?
|
| HLA-A Antigens | 1 | 2021 | 232 | 0.190 |
Why?
|
| Pyridines | 1 | 2012 | 2825 | 0.190 |
Why?
|
| Trust | 3 | 2013 | 505 | 0.180 |
Why?
|
| Demography | 3 | 2024 | 1655 | 0.180 |
Why?
|
| Venous Thromboembolism | 2 | 2024 | 1671 | 0.180 |
Why?
|
| Hospital Bed Capacity, 100 to 299 | 2 | 2012 | 11 | 0.180 |
Why?
|
| Delayed-Action Preparations | 2 | 2002 | 968 | 0.180 |
Why?
|
| Child Health Services | 2 | 2007 | 667 | 0.180 |
Why?
|
| Consumer Advocacy | 1 | 2000 | 81 | 0.180 |
Why?
|
| Supratentorial Neoplasms | 1 | 2021 | 160 | 0.180 |
Why?
|
| Physical Examination | 4 | 2001 | 1237 | 0.180 |
Why?
|
| Therapy, Computer-Assisted | 2 | 1999 | 271 | 0.180 |
Why?
|
| Hypothyroidism | 2 | 2004 | 658 | 0.180 |
Why?
|
| Biomedical Research | 4 | 2010 | 3309 | 0.180 |
Why?
|
| Mood Disorders | 1 | 2006 | 1106 | 0.180 |
Why?
|
| Antidotes | 1 | 2000 | 138 | 0.180 |
Why?
|
| Economics, Medical | 2 | 2018 | 113 | 0.180 |
Why?
|
| Follow-Up Studies | 17 | 2019 | 39052 | 0.180 |
Why?
|
| Interdisciplinary Communication | 4 | 2019 | 950 | 0.180 |
Why?
|
| Treatment Outcome | 18 | 2021 | 63107 | 0.170 |
Why?
|
| Statistics as Topic | 6 | 2011 | 2373 | 0.170 |
Why?
|
| Minority Groups | 2 | 2023 | 1221 | 0.170 |
Why?
|
| Chromosomes | 1 | 2023 | 596 | 0.170 |
Why?
|
| Liver Cirrhosis | 1 | 2009 | 1862 | 0.170 |
Why?
|
| HLA-B Antigens | 1 | 2021 | 354 | 0.170 |
Why?
|
| Gram-Negative Bacterial Infections | 3 | 1998 | 232 | 0.170 |
Why?
|
| Digestive System Diseases | 1 | 2001 | 147 | 0.170 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2002 | 386 | 0.170 |
Why?
|
| Utilization Review | 5 | 2015 | 392 | 0.170 |
Why?
|
| Sensitivity and Specificity | 11 | 2012 | 14723 | 0.170 |
Why?
|
| Fractures, Bone | 5 | 2020 | 1947 | 0.170 |
Why?
|
| Hospitals, General | 1 | 2023 | 749 | 0.170 |
Why?
|
| Pharmacy | 1 | 2021 | 91 | 0.170 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2004 | 789 | 0.170 |
Why?
|
| Paroxetine | 1 | 2020 | 182 | 0.170 |
Why?
|
| Reimbursement Mechanisms | 3 | 2015 | 670 | 0.170 |
Why?
|
| Acetylcysteine | 1 | 2000 | 271 | 0.170 |
Why?
|
| Limulus Test | 1 | 1998 | 19 | 0.170 |
Why?
|
| Sleep Deprivation | 3 | 2019 | 832 | 0.170 |
Why?
|
| Diverticulitis | 1 | 2021 | 171 | 0.170 |
Why?
|
| Joint Diseases | 2 | 2001 | 479 | 0.170 |
Why?
|
| Expert Systems | 3 | 2003 | 81 | 0.170 |
Why?
|
| Postoperative Period | 2 | 2021 | 1842 | 0.170 |
Why?
|
| Kidney Transplantation | 1 | 2014 | 4251 | 0.170 |
Why?
|
| Work | 1 | 2020 | 191 | 0.160 |
Why?
|
| Ancillary Services, Hospital | 1 | 1998 | 23 | 0.160 |
Why?
|
| Sertraline | 1 | 2020 | 206 | 0.160 |
Why?
|
| Blood Pressure | 6 | 2021 | 8551 | 0.160 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2019 | 923 | 0.160 |
Why?
|
| Depressive Disorder | 4 | 2006 | 3747 | 0.160 |
Why?
|
| Cell Cycle | 2 | 2014 | 2967 | 0.160 |
Why?
|
| Multi-Institutional Systems | 4 | 2005 | 43 | 0.160 |
Why?
|
| Infant, Newborn | 10 | 2024 | 25628 | 0.160 |
Why?
|
| DNA | 2 | 2023 | 7294 | 0.160 |
Why?
|
| Antibodies, Antinuclear | 1 | 1999 | 326 | 0.160 |
Why?
|
| Feasibility Studies | 4 | 2023 | 5077 | 0.160 |
Why?
|
| Vitamin K | 1 | 2000 | 295 | 0.160 |
Why?
|
| Hospital Bed Capacity | 1 | 2019 | 215 | 0.160 |
Why?
|
| Wakefulness | 3 | 2021 | 1245 | 0.160 |
Why?
|
| Cerebrovascular Disorders | 9 | 2005 | 1504 | 0.160 |
Why?
|
| Mutagenesis | 2 | 2019 | 1264 | 0.160 |
Why?
|
| Writing | 1 | 2000 | 206 | 0.160 |
Why?
|
| Longitudinal Studies | 8 | 2019 | 13991 | 0.160 |
Why?
|
| Digoxin | 1 | 1999 | 250 | 0.160 |
Why?
|
| Awards and Prizes | 1 | 2002 | 375 | 0.160 |
Why?
|
| Epidemiologic Studies | 1 | 2021 | 676 | 0.160 |
Why?
|
| Influenza, Human | 2 | 2006 | 1479 | 0.160 |
Why?
|
| Cardiovascular Diseases | 5 | 2020 | 15160 | 0.150 |
Why?
|
| Fungemia | 1 | 1997 | 53 | 0.150 |
Why?
|
| Equipment Failure | 3 | 2018 | 578 | 0.150 |
Why?
|
| Potassium | 2 | 2019 | 1336 | 0.150 |
Why?
|
| Monte Carlo Method | 2 | 2021 | 1254 | 0.150 |
Why?
|
| Serologic Tests | 1 | 1999 | 374 | 0.150 |
Why?
|
| Bacteriological Techniques | 2 | 2006 | 277 | 0.150 |
Why?
|
| Diagnostic Imaging | 3 | 2006 | 3508 | 0.150 |
Why?
|
| Photography | 1 | 2020 | 520 | 0.150 |
Why?
|
| Kidney Function Tests | 1 | 2019 | 683 | 0.150 |
Why?
|
| Laboratories, Hospital | 4 | 2017 | 194 | 0.150 |
Why?
|
| DNA, Cruciform | 1 | 2016 | 11 | 0.150 |
Why?
|
| Genome, Bacterial | 1 | 2022 | 760 | 0.150 |
Why?
|
| Financing, Government | 3 | 2013 | 468 | 0.150 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2023 | 781 | 0.150 |
Why?
|
| Foreign Bodies | 1 | 2021 | 400 | 0.150 |
Why?
|
| Geriatric Nursing | 1 | 2017 | 39 | 0.150 |
Why?
|
| Rheumatology | 2 | 2000 | 576 | 0.150 |
Why?
|
| DNA Breaks, Single-Stranded | 1 | 2016 | 23 | 0.140 |
Why?
|
| Societies, Medical | 3 | 2009 | 3743 | 0.140 |
Why?
|
| Surgical Procedures, Operative | 2 | 2009 | 1877 | 0.140 |
Why?
|
| RecQ Helicases | 1 | 2016 | 54 | 0.140 |
Why?
|
| Prediabetic State | 1 | 2022 | 499 | 0.140 |
Why?
|
| Antiviral Agents | 2 | 2006 | 2987 | 0.140 |
Why?
|
| Laboratories | 2 | 2017 | 463 | 0.140 |
Why?
|
| Physician's Role | 3 | 2012 | 943 | 0.140 |
Why?
|
| Prognosis | 11 | 2016 | 29060 | 0.140 |
Why?
|
| Goals | 2 | 2019 | 707 | 0.140 |
Why?
|
| Registries | 6 | 2019 | 8091 | 0.140 |
Why?
|
| Matched-Pair Analysis | 2 | 2013 | 288 | 0.140 |
Why?
|
| Indiana | 1 | 2016 | 92 | 0.140 |
Why?
|
| Linear Models | 7 | 2022 | 5953 | 0.140 |
Why?
|
| Transsexualism | 1 | 2019 | 178 | 0.140 |
Why?
|
| Pharmacopoeias as Topic | 2 | 2006 | 17 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 4 | 2016 | 2535 | 0.140 |
Why?
|
| Journal Impact Factor | 1 | 2017 | 156 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2018 | 2282 | 0.140 |
Why?
|
| Air Pollution | 2 | 2007 | 2286 | 0.140 |
Why?
|
| Utah | 2 | 2019 | 126 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2005 | 1580 | 0.130 |
Why?
|
| Rheumatic Diseases | 2 | 1999 | 593 | 0.130 |
Why?
|
| Respiratory Tract Infections | 2 | 2018 | 961 | 0.130 |
Why?
|
| Bone Density | 3 | 2004 | 3468 | 0.130 |
Why?
|
| Cardiotonic Agents | 1 | 1999 | 535 | 0.130 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 711 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 3 | 2006 | 2494 | 0.130 |
Why?
|
| Home Care Services | 1 | 2002 | 606 | 0.130 |
Why?
|
| Penicillins | 1 | 2018 | 380 | 0.130 |
Why?
|
| Cross-Cultural Comparison | 1 | 2019 | 651 | 0.130 |
Why?
|
| Cluster Analysis | 1 | 2022 | 2715 | 0.130 |
Why?
|
| Hospitals, Special | 1 | 2016 | 101 | 0.130 |
Why?
|
| Regional Medical Programs | 2 | 2006 | 71 | 0.130 |
Why?
|
| Stroke | 4 | 2017 | 9981 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2020 | 3047 | 0.130 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 20824 | 0.130 |
Why?
|
| Opioid-Related Disorders | 3 | 2021 | 2064 | 0.130 |
Why?
|
| Patient Advocacy | 1 | 2017 | 353 | 0.130 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2003 | 1873 | 0.130 |
Why?
|
| Microbiological Techniques | 2 | 2015 | 102 | 0.130 |
Why?
|
| Remote Sensing Technology | 1 | 2016 | 90 | 0.130 |
Why?
|
| Urinary Tract Infections | 2 | 2015 | 788 | 0.130 |
Why?
|
| Hypoglycemia | 1 | 2002 | 861 | 0.130 |
Why?
|
| Sex Distribution | 5 | 2013 | 2297 | 0.130 |
Why?
|
| Patient Preference | 2 | 2019 | 889 | 0.130 |
Why?
|
| Antineoplastic Agents | 3 | 2012 | 13693 | 0.130 |
Why?
|
| Hospitalists | 1 | 1999 | 305 | 0.130 |
Why?
|
| Risk Sharing, Financial | 3 | 1999 | 47 | 0.130 |
Why?
|
| Knee Joint | 3 | 2001 | 1680 | 0.120 |
Why?
|
| Abdomen | 1 | 2001 | 1118 | 0.120 |
Why?
|
| Probability | 5 | 2004 | 2506 | 0.120 |
Why?
|
| Smoking | 4 | 2010 | 8987 | 0.120 |
Why?
|
| Age Distribution | 6 | 2013 | 2902 | 0.120 |
Why?
|
| Sumatriptan | 1 | 1994 | 65 | 0.120 |
Why?
|
| Coronary Disease | 5 | 2013 | 6077 | 0.120 |
Why?
|
| Speech | 1 | 2019 | 541 | 0.120 |
Why?
|
| Models, Econometric | 3 | 2000 | 218 | 0.120 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 3 | 2005 | 93 | 0.120 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2016 | 371 | 0.120 |
Why?
|
| Phlebotomy | 2 | 2017 | 141 | 0.120 |
Why?
|
| Radiography, Abdominal | 1 | 1997 | 537 | 0.120 |
Why?
|
| Angioplasty | 1 | 1997 | 364 | 0.120 |
Why?
|
| North America | 2 | 2020 | 1249 | 0.120 |
Why?
|
| Child | 23 | 2023 | 77709 | 0.120 |
Why?
|
| Computer Simulation | 5 | 2017 | 6194 | 0.120 |
Why?
|
| Shoulder Joint | 2 | 2001 | 695 | 0.120 |
Why?
|
| Kidney | 3 | 2018 | 7184 | 0.120 |
Why?
|
| Planning Techniques | 2 | 2004 | 82 | 0.120 |
Why?
|
| Health Status | 4 | 2007 | 4034 | 0.120 |
Why?
|
| Acetaminophen | 2 | 2012 | 545 | 0.120 |
Why?
|
| Equipment Safety | 1 | 2014 | 263 | 0.120 |
Why?
|
| Statistics, Nonparametric | 3 | 2020 | 2887 | 0.120 |
Why?
|
| Lead Poisoning | 1 | 2016 | 301 | 0.120 |
Why?
|
| Prescriptions | 1 | 2016 | 387 | 0.120 |
Why?
|
| Legislation, Drug | 2 | 2010 | 206 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 2022 | 1102 | 0.120 |
Why?
|
| Streptococcus pyogenes | 2 | 2006 | 289 | 0.120 |
Why?
|
| Task Performance and Analysis | 5 | 2020 | 780 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 2 | 2005 | 9274 | 0.120 |
Why?
|
| Diagnosis, Differential | 5 | 2024 | 12961 | 0.120 |
Why?
|
| Disinfection | 1 | 2015 | 191 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2022 | 1199 | 0.110 |
Why?
|
| Reference Standards | 2 | 2017 | 1025 | 0.110 |
Why?
|
| Quality of Life | 4 | 2024 | 12802 | 0.110 |
Why?
|
| Faculty, Medical | 2 | 2019 | 1181 | 0.110 |
Why?
|
| Hospital-Patient Relations | 1 | 2013 | 16 | 0.110 |
Why?
|
| Investments | 2 | 2013 | 143 | 0.110 |
Why?
|
| Systems Analysis | 4 | 2006 | 172 | 0.110 |
Why?
|
| Insurance Claim Reporting | 1 | 2013 | 163 | 0.110 |
Why?
|
| Diabetes, Gestational | 2 | 2015 | 1184 | 0.110 |
Why?
|
| Licensure | 1 | 2014 | 125 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 3 | 2021 | 1677 | 0.110 |
Why?
|
| Hospital Bed Capacity, 500 and over | 3 | 1997 | 115 | 0.110 |
Why?
|
| Asthma, Aspirin-Induced | 1 | 2016 | 182 | 0.110 |
Why?
|
| Memory, Short-Term | 1 | 2019 | 977 | 0.110 |
Why?
|
| Proxy | 1 | 2014 | 145 | 0.110 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2019 | 1035 | 0.110 |
Why?
|
| Self Administration | 1 | 2014 | 385 | 0.110 |
Why?
|
| Triage | 2 | 2014 | 977 | 0.110 |
Why?
|
| Accreditation | 2 | 2014 | 452 | 0.110 |
Why?
|
| Disease | 1 | 2018 | 680 | 0.110 |
Why?
|
| Phenytoin | 3 | 1998 | 197 | 0.110 |
Why?
|
| Respiratory Rate | 1 | 2013 | 162 | 0.110 |
Why?
|
| Health Surveys | 5 | 2016 | 4036 | 0.110 |
Why?
|
| Feedback, Psychological | 1 | 2012 | 97 | 0.110 |
Why?
|
| Analgesics, Non-Narcotic | 3 | 2012 | 366 | 0.110 |
Why?
|
| Fever | 2 | 2012 | 1616 | 0.110 |
Why?
|
| False Positive Reactions | 5 | 2006 | 980 | 0.110 |
Why?
|
| Counseling | 2 | 2018 | 1523 | 0.110 |
Why?
|
| Child, Preschool | 12 | 2016 | 41005 | 0.110 |
Why?
|
| Clinical Medicine | 1 | 1994 | 147 | 0.110 |
Why?
|
| Catheter-Related Infections | 1 | 2015 | 252 | 0.110 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2015 | 336 | 0.100 |
Why?
|
| Mortality | 2 | 2018 | 2864 | 0.100 |
Why?
|
| Capacity Building | 2 | 2013 | 248 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2021 | 10943 | 0.100 |
Why?
|
| DNA Damage | 2 | 2019 | 2432 | 0.100 |
Why?
|
| Operating Rooms | 2 | 2015 | 817 | 0.100 |
Why?
|
| Motivation | 1 | 2022 | 1971 | 0.100 |
Why?
|
| Electron Spin Resonance Spectroscopy | 2 | 2022 | 165 | 0.100 |
Why?
|
| Perioperative Period | 1 | 2013 | 256 | 0.100 |
Why?
|
| General Surgery | 2 | 2022 | 1636 | 0.100 |
Why?
|
| Ticlopidine | 1 | 2017 | 899 | 0.100 |
Why?
|
| Arthritis | 1 | 1997 | 661 | 0.100 |
Why?
|
| Recombination, Genetic | 1 | 2016 | 1586 | 0.100 |
Why?
|
| Streptococcal Infections | 2 | 2006 | 638 | 0.100 |
Why?
|
| Least-Squares Analysis | 1 | 2012 | 379 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2021 | 1470 | 0.100 |
Why?
|
| Disease Progression | 2 | 2019 | 13286 | 0.100 |
Why?
|
| Nurse Practitioners | 1 | 2014 | 269 | 0.100 |
Why?
|
| New Mexico | 2 | 2001 | 86 | 0.100 |
Why?
|
| Knowledge Management | 1 | 2011 | 6 | 0.100 |
Why?
|
| Frail Elderly | 1 | 2016 | 693 | 0.100 |
Why?
|
| Hemorrhage | 4 | 2022 | 3461 | 0.100 |
Why?
|
| Nafronyl | 1 | 1990 | 1 | 0.100 |
Why?
|
| Nasal Polyps | 1 | 2016 | 360 | 0.100 |
Why?
|
| Narcotics | 1 | 2013 | 343 | 0.100 |
Why?
|
| Lipids | 1 | 2022 | 3307 | 0.100 |
Why?
|
| Allergens | 4 | 2022 | 1320 | 0.100 |
Why?
|
| Gingival Diseases | 1 | 2011 | 34 | 0.100 |
Why?
|
| Liver Failure, Acute | 1 | 2012 | 165 | 0.100 |
Why?
|
| Emergency Treatment | 2 | 2007 | 517 | 0.100 |
Why?
|
| Public Health Practice | 1 | 2013 | 218 | 0.090 |
Why?
|
| Politics | 1 | 2017 | 791 | 0.090 |
Why?
|
| Coronary Artery Disease | 2 | 2014 | 6486 | 0.090 |
Why?
|
| Semantics | 1 | 2014 | 585 | 0.090 |
Why?
|
| Angiogenic Proteins | 1 | 2011 | 104 | 0.090 |
Why?
|
| Orthopedics | 1 | 2000 | 904 | 0.090 |
Why?
|
| Colorado | 5 | 2018 | 163 | 0.090 |
Why?
|
| Shoulder Pain | 3 | 2001 | 144 | 0.090 |
Why?
|
| Organization and Administration | 1 | 2010 | 52 | 0.090 |
Why?
|
| Genome-Wide Association Study | 2 | 2020 | 12262 | 0.090 |
Why?
|
| Antipsychotic Agents | 1 | 2003 | 3057 | 0.090 |
Why?
|
| Advisory Committees | 1 | 2014 | 775 | 0.090 |
Why?
|
| Risk | 7 | 2018 | 9688 | 0.090 |
Why?
|
| Hospital Rapid Response Team | 1 | 2010 | 57 | 0.090 |
Why?
|
| California | 3 | 2021 | 1402 | 0.090 |
Why?
|
| Switzerland | 1 | 2009 | 256 | 0.090 |
Why?
|
| Electronics, Medical | 1 | 2009 | 71 | 0.090 |
Why?
|
| Atrial Fibrillation | 2 | 2019 | 5035 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 1240 | 0.090 |
Why?
|
| Developing Countries | 2 | 2013 | 2815 | 0.090 |
Why?
|
| DNA Repair | 1 | 2019 | 2046 | 0.090 |
Why?
|
| Preventive Health Services | 2 | 2007 | 575 | 0.090 |
Why?
|
| Central Nervous System Agents | 1 | 2009 | 72 | 0.090 |
Why?
|
| Educational Measurement | 2 | 2016 | 1210 | 0.090 |
Why?
|
| Concept Formation | 1 | 2010 | 158 | 0.090 |
Why?
|
| Automation | 1 | 2012 | 584 | 0.090 |
Why?
|
| Infant | 10 | 2023 | 35134 | 0.080 |
Why?
|
| Security Measures | 1 | 2009 | 77 | 0.080 |
Why?
|
| Time | 3 | 2013 | 542 | 0.080 |
Why?
|
| Netherlands | 3 | 2020 | 2170 | 0.080 |
Why?
|
| Self Report | 2 | 2017 | 3553 | 0.080 |
Why?
|
| Anesthetics | 1 | 2015 | 539 | 0.080 |
Why?
|
| Australasia | 1 | 2008 | 19 | 0.080 |
Why?
|
| Hospitals, Group Practice | 1 | 2008 | 4 | 0.080 |
Why?
|
| Platelet Count | 2 | 2003 | 780 | 0.080 |
Why?
|
| Cognition | 2 | 2023 | 6770 | 0.080 |
Why?
|
| Sulfonamides | 1 | 2018 | 1940 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2018 | 2108 | 0.080 |
Why?
|
| Cicatrix | 1 | 2014 | 764 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8642 | 0.080 |
Why?
|
| Gingiva | 1 | 2011 | 388 | 0.080 |
Why?
|
| Withholding Treatment | 1 | 2013 | 599 | 0.080 |
Why?
|
| Nephrology | 3 | 2018 | 263 | 0.080 |
Why?
|
| Heart Diseases | 2 | 2014 | 2789 | 0.080 |
Why?
|
| Health Expenditures | 4 | 2009 | 2349 | 0.080 |
Why?
|
| Radiology Department, Hospital | 2 | 2006 | 412 | 0.080 |
Why?
|
| Genomics | 2 | 2016 | 5717 | 0.080 |
Why?
|
| Anesthesia | 2 | 2015 | 1561 | 0.080 |
Why?
|
| Aerosols | 1 | 2010 | 625 | 0.080 |
Why?
|
| Morbidity | 2 | 2012 | 1768 | 0.080 |
Why?
|
| Institutional Management Teams | 2 | 2006 | 31 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2022 | 7721 | 0.080 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 9647 | 0.080 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2014 | 964 | 0.080 |
Why?
|
| Insurance Claim Review | 1 | 2012 | 720 | 0.080 |
Why?
|
| Health Planning Guidelines | 2 | 2011 | 163 | 0.080 |
Why?
|
| Kidney Glomerulus | 1 | 2010 | 697 | 0.080 |
Why?
|
| Nurse's Role | 2 | 2008 | 209 | 0.080 |
Why?
|
| Social Support | 1 | 2017 | 2118 | 0.080 |
Why?
|
| Systematized Nomenclature of Medicine | 2 | 2018 | 36 | 0.070 |
Why?
|
| Bed Occupancy | 1 | 2007 | 41 | 0.070 |
Why?
|
| Regional Health Planning | 1 | 2007 | 97 | 0.070 |
Why?
|
| Terminal Care | 1 | 2019 | 1694 | 0.070 |
Why?
|
| Prostate | 2 | 2006 | 1775 | 0.070 |
Why?
|
| Medicare Part C | 2 | 2003 | 296 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2023 | 12721 | 0.070 |
Why?
|
| Health Care Coalitions | 1 | 2006 | 35 | 0.070 |
Why?
|
| Keratinocytes | 1 | 2011 | 799 | 0.070 |
Why?
|
| Mental Health Services | 1 | 2018 | 1644 | 0.070 |
Why?
|
| Hospital Records | 2 | 1999 | 95 | 0.070 |
Why?
|
| MedlinePlus | 1 | 2006 | 4 | 0.070 |
Why?
|
| Social Isolation | 1 | 2009 | 365 | 0.070 |
Why?
|
| Osteoporotic Fractures | 1 | 2011 | 401 | 0.070 |
Why?
|
| Podocytes | 1 | 2010 | 396 | 0.070 |
Why?
|
| Phenobarbital | 2 | 1998 | 193 | 0.070 |
Why?
|
| Formularies as Topic | 1 | 2006 | 91 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2021 | 13035 | 0.070 |
Why?
|
| Carbamazepine | 2 | 1998 | 229 | 0.070 |
Why?
|
| Heel | 2 | 2002 | 36 | 0.070 |
Why?
|
| Spinal Cord Compression | 1 | 1988 | 235 | 0.070 |
Why?
|
| Naproxen | 1 | 2006 | 99 | 0.070 |
Why?
|
| Knee Injuries | 2 | 2001 | 490 | 0.070 |
Why?
|
| Health Maintenance Organizations | 2 | 2001 | 642 | 0.070 |
Why?
|
| International Agencies | 1 | 2006 | 240 | 0.070 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2006 | 170 | 0.070 |
Why?
|
| Korea | 1 | 2005 | 99 | 0.070 |
Why?
|
| Poisson Distribution | 1 | 2007 | 513 | 0.070 |
Why?
|
| Shoulder | 1 | 1988 | 299 | 0.070 |
Why?
|
| Causality | 2 | 2016 | 1275 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2001 | 3255 | 0.070 |
Why?
|
| Nicotine | 1 | 2010 | 681 | 0.070 |
Why?
|
| Vaginal Smears | 1 | 2008 | 511 | 0.070 |
Why?
|
| Prostatic Neoplasms | 4 | 2006 | 11126 | 0.070 |
Why?
|
| Equipment Design | 2 | 2005 | 3582 | 0.070 |
Why?
|
| Research Support as Topic | 2 | 2009 | 705 | 0.070 |
Why?
|
| Hemodynamics | 1 | 2016 | 4196 | 0.070 |
Why?
|
| Hospitals, Pediatric | 3 | 2008 | 1775 | 0.070 |
Why?
|
| Lorazepam | 1 | 2006 | 145 | 0.070 |
Why?
|
| Parasympatholytics | 1 | 2005 | 91 | 0.070 |
Why?
|
| Risk Adjustment | 2 | 2000 | 594 | 0.070 |
Why?
|
| Attitude to Death | 1 | 1988 | 382 | 0.060 |
Why?
|
| Comparative Effectiveness Research | 3 | 2018 | 680 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 1997 | 4576 | 0.060 |
Why?
|
| Dementia | 1 | 2019 | 2518 | 0.060 |
Why?
|
| Spasm | 1 | 2005 | 121 | 0.060 |
Why?
|
| Case Management | 2 | 2011 | 286 | 0.060 |
Why?
|
| Adhesins, Bacterial | 1 | 2005 | 119 | 0.060 |
Why?
|
| Robotics | 1 | 2012 | 899 | 0.060 |
Why?
|
| Staff Development | 2 | 2019 | 223 | 0.060 |
Why?
|
| Community Health Centers | 1 | 2008 | 430 | 0.060 |
Why?
|
| Flagellin | 1 | 2005 | 125 | 0.060 |
Why?
|
| Correspondence as Topic | 1 | 2004 | 27 | 0.060 |
Why?
|
| Medically Underserved Area | 1 | 2007 | 253 | 0.060 |
Why?
|
| Hematocrit | 2 | 2001 | 636 | 0.060 |
Why?
|
| Antigens, CD20 | 1 | 2005 | 199 | 0.060 |
Why?
|
| Injury Severity Score | 2 | 2020 | 1014 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2005 | 6489 | 0.060 |
Why?
|
| Renin-Angiotensin System | 2 | 2019 | 758 | 0.060 |
Why?
|
| Hip | 2 | 2002 | 257 | 0.060 |
Why?
|
| Glutamate Decarboxylase | 1 | 2005 | 245 | 0.060 |
Why?
|
| Neuromuscular Diseases | 1 | 1987 | 247 | 0.060 |
Why?
|
| Musculoskeletal Diseases | 3 | 2001 | 581 | 0.060 |
Why?
|
| Palliative Care | 1 | 2019 | 3493 | 0.060 |
Why?
|
| Education, Nursing | 1 | 2004 | 82 | 0.060 |
Why?
|
| Multiple Organ Failure | 1 | 2006 | 389 | 0.060 |
Why?
|
| Candidiasis | 1 | 2006 | 366 | 0.060 |
Why?
|
| Public Health Informatics | 1 | 2005 | 110 | 0.060 |
Why?
|
| Tissue Scaffolds | 1 | 2011 | 956 | 0.060 |
Why?
|
| Back Pain | 1 | 1988 | 545 | 0.060 |
Why?
|
| New York | 2 | 2020 | 886 | 0.060 |
Why?
|
| Bacterial Adhesion | 1 | 2005 | 316 | 0.060 |
Why?
|
| Bacteria | 1 | 2014 | 2115 | 0.060 |
Why?
|
| Truth Disclosure | 1 | 2008 | 436 | 0.060 |
Why?
|
| Pharynx | 1 | 2006 | 413 | 0.060 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2014 | 1209 | 0.060 |
Why?
|
| Germany | 1 | 2006 | 862 | 0.060 |
Why?
|
| Candida albicans | 1 | 2006 | 394 | 0.060 |
Why?
|
| Pharmacy and Therapeutics Committee | 1 | 2003 | 9 | 0.060 |
Why?
|
| Developed Countries | 1 | 2006 | 437 | 0.060 |
Why?
|
| Plasma | 1 | 2007 | 575 | 0.060 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2003 | 86 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2008 | 430 | 0.060 |
Why?
|
| Simvastatin | 1 | 2006 | 360 | 0.060 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 850 | 0.060 |
Why?
|
| Intraoperative Complications | 2 | 2009 | 1198 | 0.060 |
Why?
|
| Observer Variation | 3 | 2018 | 2593 | 0.060 |
Why?
|
| Man-Machine Systems | 1 | 2003 | 44 | 0.060 |
Why?
|
| Maine | 1 | 2003 | 139 | 0.060 |
Why?
|
| Rural Health Services | 1 | 2007 | 379 | 0.060 |
Why?
|
| Educational Status | 3 | 2010 | 2540 | 0.060 |
Why?
|
| Patient Isolation | 1 | 2003 | 100 | 0.060 |
Why?
|
| Ontario | 1 | 2004 | 383 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2005 | 623 | 0.050 |
Why?
|
| Informed Consent | 1 | 2009 | 995 | 0.050 |
Why?
|
| Hydroxylamines | 1 | 2022 | 40 | 0.050 |
Why?
|
| Muscles | 1 | 1988 | 1614 | 0.050 |
Why?
|
| Self-Assessment | 1 | 2005 | 390 | 0.050 |
Why?
|
| World Health Organization | 3 | 2013 | 1318 | 0.050 |
Why?
|
| Ivermectin | 1 | 2022 | 42 | 0.050 |
Why?
|
| Disability Evaluation | 2 | 2008 | 1828 | 0.050 |
Why?
|
| China | 2 | 2022 | 2245 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2011 | 3511 | 0.050 |
Why?
|
| Sleep | 5 | 2021 | 4622 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2006 | 3914 | 0.050 |
Why?
|
| Heart Rate | 1 | 2013 | 4092 | 0.050 |
Why?
|
| Cytidine | 1 | 2022 | 68 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2000 | 1683 | 0.050 |
Why?
|
| Early Detection of Cancer | 2 | 2014 | 3086 | 0.050 |
Why?
|
| Professional-Family Relations | 2 | 2018 | 482 | 0.050 |
Why?
|
| Thyroid Diseases | 2 | 1996 | 379 | 0.050 |
Why?
|
| Delivery, Obstetric | 1 | 2009 | 906 | 0.050 |
Why?
|
| Evoked Potentials, Motor | 1 | 2005 | 454 | 0.050 |
Why?
|
| Migraine Disorders | 1 | 1994 | 1620 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2005 | 693 | 0.050 |
Why?
|
| Diabetes Complications | 2 | 2005 | 1359 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2012 | 2971 | 0.050 |
Why?
|
| Medicare Part B | 1 | 2003 | 108 | 0.050 |
Why?
|
| Spirometry | 2 | 2021 | 865 | 0.050 |
Why?
|
| Culture Media | 3 | 1998 | 909 | 0.050 |
Why?
|
| Motor Neurons | 1 | 1987 | 844 | 0.050 |
Why?
|
| Uncertainty | 1 | 2007 | 735 | 0.050 |
Why?
|
| Aftercare | 1 | 2008 | 870 | 0.050 |
Why?
|
| Personhood | 1 | 2021 | 30 | 0.050 |
Why?
|
| Societies, Pharmaceutical | 1 | 2021 | 3 | 0.050 |
Why?
|
| Skilled Nursing Facilities | 2 | 2002 | 372 | 0.050 |
Why?
|
| Insurance, Health | 2 | 2012 | 2494 | 0.050 |
Why?
|
| Infusions, Parenteral | 1 | 2001 | 419 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 4933 | 0.050 |
Why?
|
| Neutropenia | 1 | 2006 | 895 | 0.050 |
Why?
|
| Neurology | 1 | 2009 | 763 | 0.050 |
Why?
|
| Hypertension, Renal | 1 | 2001 | 177 | 0.050 |
Why?
|
| Nizatidine | 1 | 2000 | 7 | 0.050 |
Why?
|
| Life Style | 1 | 2013 | 3835 | 0.050 |
Why?
|
| Gastric Lavage | 1 | 2000 | 18 | 0.050 |
Why?
|
| New Jersey | 1 | 2021 | 290 | 0.050 |
Why?
|
| Administrative Personnel | 2 | 2015 | 187 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 15520 | 0.050 |
Why?
|
| Off-Label Use | 1 | 2022 | 169 | 0.050 |
Why?
|
| Recurrence | 2 | 2005 | 8340 | 0.050 |
Why?
|
| Body Weight | 2 | 2017 | 4671 | 0.050 |
Why?
|
| Spinal Neoplasms | 1 | 1988 | 760 | 0.050 |
Why?
|
| Social Responsibility | 1 | 2003 | 388 | 0.050 |
Why?
|
| Breast Diseases | 1 | 2004 | 443 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2006 | 2618 | 0.050 |
Why?
|
| MEDLARS | 1 | 2000 | 5 | 0.050 |
Why?
|
| Health Promotion | 1 | 2013 | 2205 | 0.050 |
Why?
|
| Inhalation Exposure | 1 | 2003 | 443 | 0.050 |
Why?
|
| Nursing Research | 1 | 2021 | 77 | 0.050 |
Why?
|
| Health Status Indicators | 1 | 2006 | 970 | 0.050 |
Why?
|
| Models, Organizational | 2 | 2018 | 574 | 0.050 |
Why?
|
| Azabicyclo Compounds | 1 | 2000 | 68 | 0.050 |
Why?
|
| Environmental Monitoring | 2 | 2004 | 1414 | 0.050 |
Why?
|
| Ultrasonography | 3 | 2002 | 5984 | 0.050 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 199 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1988 | 1381 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2011 | 4162 | 0.050 |
Why?
|
| Cost Allocation | 1 | 2000 | 51 | 0.050 |
Why?
|
| Electromyography | 1 | 2005 | 1379 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 8861 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2024 | 441 | 0.050 |
Why?
|
| Respiration Disorders | 1 | 2003 | 371 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2015 | 3537 | 0.040 |
Why?
|
| Digestive System | 1 | 2001 | 253 | 0.040 |
Why?
|
| Ondansetron | 1 | 2000 | 90 | 0.040 |
Why?
|
| Microscopy | 1 | 2005 | 902 | 0.040 |
Why?
|
| Integrated Advanced Information Management Systems | 1 | 1999 | 8 | 0.040 |
Why?
|
| Minnesota | 1 | 2000 | 344 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2009 | 2158 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2005 | 1364 | 0.040 |
Why?
|
| Learning | 1 | 2009 | 1711 | 0.040 |
Why?
|
| Quarantine | 1 | 2022 | 170 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2002 | 404 | 0.040 |
Why?
|
| Absorptiometry, Photon | 2 | 2002 | 1725 | 0.040 |
Why?
|
| Los Angeles | 2 | 2014 | 238 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2009 | 6539 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2004 | 1745 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2013 | 17446 | 0.040 |
Why?
|
| Rheumatoid Factor | 1 | 1999 | 188 | 0.040 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 1513 | 0.040 |
Why?
|
| Child Welfare | 1 | 2003 | 523 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 2219 | 0.040 |
Why?
|
| APACHE | 2 | 2013 | 277 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2006 | 981 | 0.040 |
Why?
|
| Urticaria | 1 | 2000 | 150 | 0.040 |
Why?
|
| Ligaments, Articular | 1 | 2001 | 299 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2000 | 367 | 0.040 |
Why?
|
| Databases, Bibliographic | 2 | 2012 | 128 | 0.040 |
Why?
|
| Primidone | 1 | 1998 | 10 | 0.040 |
Why?
|
| Clinical Audit | 1 | 2018 | 31 | 0.040 |
Why?
|
| Hydroxychloroquine | 1 | 2022 | 412 | 0.040 |
Why?
|
| New York City | 1 | 2021 | 710 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2022 | 696 | 0.040 |
Why?
|
| Surgical Instruments | 1 | 2021 | 395 | 0.040 |
Why?
|
| Autoantibodies | 2 | 2005 | 2036 | 0.040 |
Why?
|
| Spine | 2 | 2002 | 1144 | 0.040 |
Why?
|
| Preventive Medicine | 1 | 2000 | 264 | 0.040 |
Why?
|
| Vehicle Emissions | 1 | 2003 | 665 | 0.040 |
Why?
|
| Nursing Administration Research | 2 | 2008 | 21 | 0.040 |
Why?
|
| Consciousness Disorders | 1 | 2003 | 418 | 0.040 |
Why?
|
| Mental Recall | 1 | 2005 | 1206 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2001 | 1005 | 0.040 |
Why?
|
| Belgium | 1 | 2018 | 103 | 0.040 |
Why?
|
| Antifibrinolytic Agents | 1 | 2000 | 254 | 0.040 |
Why?
|
| Sigma Factor | 1 | 2019 | 175 | 0.040 |
Why?
|
| Health Level Seven | 1 | 2017 | 38 | 0.040 |
Why?
|
| Research Report | 1 | 2021 | 355 | 0.040 |
Why?
|
| Classification | 1 | 2018 | 129 | 0.040 |
Why?
|
| Radioallergosorbent Test | 1 | 2017 | 15 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 183 | 0.040 |
Why?
|
| Communication Barriers | 1 | 2021 | 398 | 0.040 |
Why?
|
| Professional Autonomy | 1 | 1999 | 177 | 0.040 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2018 | 295 | 0.040 |
Why?
|
| Ethical Review | 1 | 1997 | 26 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 977 | 0.040 |
Why?
|
| Shellfish | 1 | 2017 | 38 | 0.040 |
Why?
|
| Heart Defects, Congenital | 1 | 2014 | 4583 | 0.040 |
Why?
|
| Communicable Diseases | 1 | 2006 | 880 | 0.040 |
Why?
|
| Policy | 1 | 2021 | 508 | 0.040 |
Why?
|
| Delphi Technique | 2 | 2013 | 779 | 0.040 |
Why?
|
| Tryptases | 1 | 2018 | 190 | 0.040 |
Why?
|
| Morphine | 1 | 2021 | 657 | 0.040 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 1997 | 89 | 0.040 |
Why?
|
| Ciprofloxacin | 1 | 2019 | 315 | 0.040 |
Why?
|
| Advance Care Planning | 1 | 2004 | 662 | 0.040 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2022 | 455 | 0.040 |
Why?
|
| Sentinel Surveillance | 1 | 1999 | 281 | 0.040 |
Why?
|
| Yeasts | 1 | 1998 | 284 | 0.040 |
Why?
|
| Clinical Trials as Topic | 3 | 2009 | 7914 | 0.040 |
Why?
|
| Gram-Negative Bacteria | 1 | 1998 | 271 | 0.040 |
Why?
|
| Information Seeking Behavior | 1 | 2018 | 113 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2009 | 2291 | 0.040 |
Why?
|
| Hyperkalemia | 1 | 2018 | 218 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 1999 | 795 | 0.030 |
Why?
|
| Quebec | 1 | 2016 | 134 | 0.030 |
Why?
|
| Computer User Training | 1 | 1996 | 19 | 0.030 |
Why?
|
| Colectomy | 1 | 2021 | 680 | 0.030 |
Why?
|
| Enzyme Multiplied Immunoassay Technique | 1 | 1995 | 7 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2016 | 189 | 0.030 |
Why?
|
| Cytotoxins | 1 | 1997 | 153 | 0.030 |
Why?
|
| Shock, Septic | 1 | 2003 | 775 | 0.030 |
Why?
|
| Rate Setting and Review | 1 | 1996 | 41 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2018 | 420 | 0.030 |
Why?
|
| Emergency Medicine | 1 | 2005 | 1205 | 0.030 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2019 | 486 | 0.030 |
Why?
|
| Urinalysis | 1 | 2018 | 369 | 0.030 |
Why?
|
| Exanthema | 1 | 2000 | 501 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2021 | 9955 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 18034 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 2 | 2018 | 2716 | 0.030 |
Why?
|
| Government | 1 | 2016 | 165 | 0.030 |
Why?
|
| Actigraphy | 1 | 2019 | 488 | 0.030 |
Why?
|
| Hospital Bed Capacity, 300 to 499 | 1 | 2014 | 60 | 0.030 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1997 | 341 | 0.030 |
Why?
|
| Consciousness | 1 | 2000 | 572 | 0.030 |
Why?
|
| Critical Pathways | 1 | 2019 | 476 | 0.030 |
Why?
|
| Sex Characteristics | 3 | 2001 | 2585 | 0.030 |
Why?
|
| Argentina | 1 | 2015 | 232 | 0.030 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1997 | 264 | 0.030 |
Why?
|
| Phenotype | 3 | 2023 | 16367 | 0.030 |
Why?
|
| Insulin | 2 | 2016 | 6582 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2005 | 5974 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2019 | 695 | 0.030 |
Why?
|
| Polymorphism, Genetic | 2 | 2002 | 4328 | 0.030 |
Why?
|
| State Government | 1 | 2017 | 372 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2024 | 1771 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 551 | 0.030 |
Why?
|
| Cardiology Service, Hospital | 1 | 1996 | 246 | 0.030 |
Why?
|
| Cognition Disorders | 2 | 2005 | 4043 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2021 | 1487 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2009 | 4245 | 0.030 |
Why?
|
| Insurance Coverage | 2 | 2022 | 1900 | 0.030 |
Why?
|
| Staphylococcus aureus | 2 | 2003 | 1453 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2005 | 2690 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 1995 | 403 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 1999 | 792 | 0.030 |
Why?
|
| Snoring | 2 | 1992 | 191 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2000 | 1301 | 0.030 |
Why?
|
| Cholesterol | 2 | 2000 | 2919 | 0.030 |
Why?
|
| Activities of Daily Living | 2 | 2008 | 2419 | 0.030 |
Why?
|
| Pneumonia | 1 | 2005 | 2133 | 0.030 |
Why?
|
| Chromosome Segregation | 1 | 2014 | 235 | 0.030 |
Why?
|
| Women's Health Services | 1 | 1994 | 93 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2017 | 365 | 0.030 |
Why?
|
| Washington | 1 | 1994 | 313 | 0.030 |
Why?
|
| Heparin | 1 | 2000 | 1637 | 0.030 |
Why?
|
| AIDS Dementia Complex | 1 | 1994 | 154 | 0.030 |
Why?
|
| Staphylococcal Infections | 2 | 2003 | 1400 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 1994 | 667 | 0.030 |
Why?
|
| Pregnancy | 4 | 2022 | 29144 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2019 | 1031 | 0.030 |
Why?
|
| Mammography | 1 | 2004 | 2475 | 0.030 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2019 | 1122 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2001 | 1161 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 1997 | 1107 | 0.030 |
Why?
|
| Health Facility Administrators | 1 | 2012 | 31 | 0.030 |
Why?
|
| Child, Hospitalized | 1 | 2014 | 174 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2007 | 4232 | 0.030 |
Why?
|
| Georgia | 2 | 2002 | 186 | 0.030 |
Why?
|
| Insurance Carriers | 1 | 2013 | 157 | 0.030 |
Why?
|
| Hallucinations | 1 | 1994 | 360 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2020 | 10252 | 0.030 |
Why?
|
| Double-Blind Method | 3 | 2002 | 12025 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1995 | 1590 | 0.020 |
Why?
|
| Psychological Tests | 1 | 1993 | 651 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2012 | 242 | 0.020 |
Why?
|
| Cell Division | 1 | 2019 | 4569 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 2076 | 0.020 |
Why?
|
| Systems Theory | 1 | 2011 | 60 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 501 | 0.020 |
Why?
|
| Angiostatins | 1 | 2011 | 67 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 1758 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 2017 | 1463 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 3873 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 1998 | 1405 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2011 | 68 | 0.020 |
Why?
|
| Gingival Crevicular Fluid | 1 | 2011 | 93 | 0.020 |
Why?
|
| Aspirin | 1 | 2023 | 3283 | 0.020 |
Why?
|
| Multifactorial Inheritance | 1 | 2018 | 1195 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 149 | 0.020 |
Why?
|
| Biometry | 1 | 1994 | 558 | 0.020 |
Why?
|
| Air Pollutants | 1 | 2004 | 2816 | 0.020 |
Why?
|
| Education, Pharmacy | 1 | 2010 | 35 | 0.020 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 2010 | 43 | 0.020 |
Why?
|
| Liability, Legal | 1 | 2011 | 213 | 0.020 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2011 | 154 | 0.020 |
Why?
|
| Latin America | 1 | 2011 | 380 | 0.020 |
Why?
|
| Piperazines | 1 | 2000 | 2488 | 0.020 |
Why?
|
| Clostridium Infections | 1 | 1997 | 548 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2011 | 251 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2000 | 3420 | 0.020 |
Why?
|
| Placebos | 1 | 1994 | 1676 | 0.020 |
Why?
|
| Chemokine CXCL10 | 1 | 2011 | 305 | 0.020 |
Why?
|
| Mice, Inbred CBA | 1 | 2010 | 448 | 0.020 |
Why?
|
| Review Literature as Topic | 1 | 2012 | 336 | 0.020 |
Why?
|
| Osteoarthritis, Knee | 1 | 2000 | 1222 | 0.020 |
Why?
|
| Influenza Vaccines | 1 | 2017 | 738 | 0.020 |
Why?
|
| Biopsy | 3 | 2006 | 6755 | 0.020 |
Why?
|
| Radiology | 1 | 2003 | 2099 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2011 | 282 | 0.020 |
Why?
|
| Lung | 2 | 2004 | 9857 | 0.020 |
Why?
|
| Delirium | 1 | 2000 | 1610 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 2 | 2010 | 2166 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2011 | 599 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 1998 | 1540 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2011 | 625 | 0.020 |
Why?
|
| Permeability | 1 | 2010 | 738 | 0.020 |
Why?
|
| Hemianopsia | 1 | 1989 | 122 | 0.020 |
Why?
|
| Nursing Methodology Research | 1 | 2008 | 67 | 0.020 |
Why?
|
| Job Description | 1 | 2008 | 58 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2021 | 3326 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2011 | 690 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 1997 | 2162 | 0.020 |
Why?
|
| Horner Syndrome | 1 | 1987 | 37 | 0.020 |
Why?
|
| Commission on Professional and Hospital Activities | 1 | 2007 | 6 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 903 | 0.020 |
Why?
|
| Management Quality Circles | 1 | 2006 | 21 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1988 | 623 | 0.020 |
Why?
|
| Capital Expenditures | 1 | 2006 | 29 | 0.020 |
Why?
|
| Family Practice | 1 | 2009 | 516 | 0.020 |
Why?
|
| Epidemiology | 1 | 2009 | 287 | 0.020 |
Why?
|
| Humerus | 1 | 1988 | 266 | 0.020 |
Why?
|
| Hypertrophy | 1 | 1988 | 569 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2010 | 694 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 1996 | 2148 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 780 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2019 | 3854 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2010 | 1117 | 0.020 |
Why?
|
| Maximal Midexpiratory Flow Rate | 1 | 2004 | 78 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 1988 | 931 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 4257 | 0.020 |
Why?
|
| Mutation | 2 | 2019 | 29786 | 0.020 |
Why?
|
| Budgets | 1 | 2006 | 229 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2013 | 1783 | 0.010 |
Why?
|
| Swine | 1 | 2014 | 5918 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 1996 | 2134 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 3707 | 0.010 |
Why?
|
| Maximum Allowable Concentration | 1 | 2003 | 62 | 0.010 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2004 | 90 | 0.010 |
Why?
|
| Computational Biology | 1 | 2016 | 3519 | 0.010 |
Why?
|
| State Health Plans | 1 | 2006 | 216 | 0.010 |
Why?
|
| Mentors | 1 | 2009 | 631 | 0.010 |
Why?
|
| Self Disclosure | 1 | 2004 | 251 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2002 | 20130 | 0.010 |
Why?
|
| Alcohol Drinking | 2 | 1993 | 3966 | 0.010 |
Why?
|
| History, 21st Century | 1 | 2009 | 1534 | 0.010 |
Why?
|
| Methicillin Resistance | 1 | 2003 | 198 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 3712 | 0.010 |
Why?
|
| Mental Health | 1 | 1996 | 3010 | 0.010 |
Why?
|
| Nitrogen Dioxide | 1 | 2004 | 490 | 0.010 |
Why?
|
| Absenteeism | 1 | 2003 | 250 | 0.010 |
Why?
|
| Vital Capacity | 1 | 2004 | 925 | 0.010 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 550 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2000 | 9240 | 0.010 |
Why?
|
| History, 20th Century | 1 | 2009 | 2740 | 0.010 |
Why?
|
| Ozone | 1 | 2004 | 469 | 0.010 |
Why?
|
| Retinal Diseases | 1 | 1987 | 684 | 0.010 |
Why?
|
| Posterior Cruciate Ligament | 1 | 2001 | 88 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2002 | 769 | 0.010 |
Why?
|
| Animals | 3 | 2023 | 168768 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 2038 | 0.010 |
Why?
|
| Hyperglycemia | 1 | 1989 | 1373 | 0.010 |
Why?
|
| Tissue Engineering | 1 | 2011 | 1880 | 0.010 |
Why?
|
| Particle Size | 1 | 2004 | 1642 | 0.010 |
Why?
|
| Brain Diseases | 1 | 1989 | 1563 | 0.010 |
Why?
|
| Blood Glucose | 2 | 1996 | 6254 | 0.010 |
Why?
|
| Wound Healing | 1 | 2011 | 2785 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1988 | 3616 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2005 | 1877 | 0.010 |
Why?
|
| Health Education | 1 | 2006 | 1056 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2019 | 12207 | 0.010 |
Why?
|
| Discriminant Analysis | 1 | 1999 | 235 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2008 | 6036 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 9735 | 0.010 |
Why?
|
| Chest Pain | 1 | 2005 | 1114 | 0.010 |
Why?
|
| Fermentation | 1 | 1998 | 144 | 0.010 |
Why?
|
| Genotype | 2 | 2002 | 12952 | 0.010 |
Why?
|
| Peer Review, Health Care | 1 | 1997 | 75 | 0.010 |
Why?
|
| Reference Values | 1 | 2004 | 4982 | 0.010 |
Why?
|
| Candida | 1 | 1998 | 172 | 0.010 |
Why?
|
| Radiography | 1 | 1988 | 7023 | 0.010 |
Why?
|
| Skinfold Thickness | 1 | 1996 | 162 | 0.010 |
Why?
|
| Eligibility Determination | 1 | 2000 | 403 | 0.010 |
Why?
|
| Prions | 1 | 1997 | 180 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2005 | 2355 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2007 | 2071 | 0.010 |
Why?
|
| Goiter | 1 | 1995 | 87 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2002 | 3587 | 0.010 |
Why?
|
| Arthroscopy | 1 | 2001 | 926 | 0.010 |
Why?
|
| Technetium Tc 99m Exametazime | 1 | 1994 | 68 | 0.010 |
Why?
|
| Organotechnetium Compounds | 1 | 1994 | 137 | 0.010 |
Why?
|
| Temperance | 1 | 1993 | 89 | 0.010 |
Why?
|
| Postmenopause | 1 | 2002 | 2460 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 2000 | 984 | 0.010 |
Why?
|
| Hyperthyroidism | 1 | 1995 | 295 | 0.010 |
Why?
|
| Organizational Policy | 1 | 1995 | 429 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 2000 | 1372 | 0.010 |
Why?
|
| Oximes | 1 | 1994 | 311 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 6171 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 21833 | 0.010 |
Why?
|
| Thyrotropin | 1 | 1995 | 849 | 0.010 |
Why?
|
| Models, Economic | 1 | 1996 | 712 | 0.010 |
Why?
|
| Anemia | 1 | 2001 | 1503 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2005 | 6442 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2001 | 2926 | 0.010 |
Why?
|
| Adaptation, Physiological | 1 | 1998 | 1312 | 0.010 |
Why?
|
| Polysaccharides | 1 | 1998 | 1059 | 0.010 |
Why?
|
| Alleles | 1 | 2002 | 6933 | 0.010 |
Why?
|
| Feces | 1 | 1997 | 1401 | 0.010 |
Why?
|
| Diarrhea | 1 | 1997 | 1348 | 0.010 |
Why?
|
| Reflex, Abnormal | 1 | 1989 | 85 | 0.010 |
Why?
|
| Hemoglobinometry | 1 | 1988 | 35 | 0.010 |
Why?
|
| Thyroid Gland | 1 | 1995 | 1173 | 0.000 |
Why?
|
| Brain | 1 | 1994 | 26388 | 0.000 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1998 | 2751 | 0.000 |
Why?
|
| Glucose Tolerance Test | 1 | 1989 | 1151 | 0.000 |
Why?
|
| Disabled Persons | 1 | 1996 | 1212 | 0.000 |
Why?
|
| Infarction | 1 | 1987 | 244 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1988 | 1588 | 0.000 |
Why?
|
| Models, Biological | 1 | 2001 | 9584 | 0.000 |
Why?
|
| Embolism | 1 | 1987 | 408 | 0.000 |
Why?
|
| Mice | 1 | 2010 | 81201 | 0.000 |
Why?
|
| Electroencephalography | 1 | 1997 | 6151 | 0.000 |
Why?
|
| Retinal Vessels | 1 | 1987 | 772 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1997 | 19233 | 0.000 |
Why?
|
| Visual Fields | 1 | 1987 | 1047 | 0.000 |
Why?
|
| Visual Acuity | 1 | 1987 | 2530 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2001 | 35425 | 0.000 |
Why?
|
| Neuropsychological Tests | 1 | 1987 | 6994 | 0.000 |
Why?
|